GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » Total Liabilities

Innovotech (TSXV:IOT) Total Liabilities : C$0.60 Mil (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Innovotech Total Liabilities?

Innovotech's Total Liabilities for the quarter that ended in Dec. 2024 was C$0.60 Mil.

Innovotech's quarterly Total Liabilities increased from Jun. 2024 (C$0.31 Mil) to Sep. 2024 (C$0.37 Mil) and increased from Sep. 2024 (C$0.37 Mil) to Dec. 2024 (C$0.60 Mil).

Innovotech's annual Total Liabilities increased from Dec. 2022 (C$0.17 Mil) to Dec. 2023 (C$0.22 Mil) and increased from Dec. 2023 (C$0.22 Mil) to Dec. 2024 (C$0.60 Mil).


Innovotech Total Liabilities Historical Data

The historical data trend for Innovotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech Total Liabilities Chart

Innovotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.26 0.17 0.22 0.60

Innovotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.22 0.31 0.37 0.60

Innovotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Innovotech's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.421+(0+0.173
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.003+0+0)
=0.60

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=3.22-2.623
=0.60

Innovotech's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.421+(0+0.173
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.003+0+0)
=0.60

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=3.22-2.623
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Innovotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovotech Business Description

Traded in Other Exchanges
N/A
Address
2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1
Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.
Executives
James Gregory Timourian Senior Officer
Bradley Alan Clark Director
Alan Clyde Hayes Savage 10% Security Holder
Craig Milne Director
David Shong-tak Tam Director
Bernard Grobbelaar Director